Bristol-Myers Squibb Company
NYSE: BMY
$49.41
+$0.39 (+0.8%)
Closing Price on September 20, 2024
BMY Articles
24/7 Wall St. has collected several big FDA decisions coming up on the calendar for the month of October and added some color.
Published:
The September 15 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest has increased.
Published:
The short interest data have been released for the August 31 settlement date, and for the selected pharmaceutical stocks, short interest is mixed.
Published:
The August 14 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks, short interest is mixed.
Published:
ThinkstockWith a very nervous market, and the end of summer doldrums upon us, it may be time to look for ideas that will make sense when the market heats back up in the fall. One area that looks very...
Published:
Bristol-Myers Squibb announced that the FDA has now extended the action date for the supplemental biologics license application for Opdivo in the war against advanced melanoma.
Published:
The short interest data have been released for the July 31 settlement date, and for most of the selected pharmaceutical stocks, short interest decreased.
Published:
24/7 Wall St. has collected several big FDA decisions coming up on the calendar for the month of August and added some color.
Published:
ThinkstockThe short interest data have been released for the July 15 settlement date. Pharmaceutical companies are usually involved in a lengthy process in getting their drug candidates to market...
Published:
Last Updated:
Bristol-Myers Squibb released better-than-expected second-quarter financial results before the markets opened Thursday.
Published:
The June 30 short interest data have been compared with the previous figures, and across the selected pharmaceutical stocks, short interest decreased.
Published:
How much are big pharmaceutical companies really spending to get their drugs out there in the public eye?
Published:
The June 15 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks, short interest is mixed.
Published:
The May 29 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest is down.
Published:
Credit Suisse has updated its autoimmune market model and it sees implications for all of the large cap U.S. pharmaceutical companies in its coverage.
Published: